Methods and means for diagnosing spondylarthritis using autoantibody markers

US9915664B2 · kind B2 · utility

Assignee

• MEDIZINISCHE HOCHSCHULE HANNOVER · DE

Inventors

• Niklas Thomas Baerlecken · Hannover, DE
• Torsten Witte · Hannover, DE

Key dates

• Filing date: Aug 16, 2011
• Grant date: Mar 13, 2018
• Expiry date: Aug 16, 2031

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/50
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

The present invention relates generally to methods for diagnosing the presence or the risk of development or the therapy control of spondyloarthritis (Spa), in particular, of ankylosing spondylitis (AS) and undifferentiated spondyloarthritis in a subject, in particular in mammals. In addition, the present invention relates to test kits for use in the diagnosis of the presence or the risk of development, or for the therapy control of Spa, like AS and undifferentiated spondyloarthritis, in a subject. In particular, the present invention relates to a method for diagnosing the presence or the risk of development, or for the therapy control of Spa, like AS and undifferentiated spondyloarthritis, in a subject analysing for the presence of autoantibodies against CD74 and/or IKBKB in a subject. The presence of autoantibodies against CD74 and/or IKBKB is indicative for the presence or the risk of development, or for the therapy control of Spa, like AS and undifferentiated spondyloarthritis. In particular, detection of the presence of autoantibodies against CD74 and/or IKBKB allows early diagnosis of Spa, in particular, AS and undifferentiated spondyloarthritis.